Monitor Q3 2026 for LIBERTY and DECLARATION topline data; positive safety/tolerability comparison could support BLA filing and differentiate VYD2311 from vaccines. Stock may trade on binary data readout risk.
Price Chart
Executive Summary
Invivyd announced completion of enrollment in its Phase 3 LIBERTY trial comparing VYD2311 (monoclonal antibody) against an mRNA COVID vaccine, with topline data expected in Q3 2026. The trial is part of the broader REVOLUTION program aiming to position VYD2311 as an alternative to vaccines. This is a clinical milestone with no efficacy or safety data yet, so the immediate stock impact is limited.
Key Facts
- Phase 3 LIBERTY trial enrollment complete; ~210 participants randomized, double-blind.
- Primary endpoint: safety/tolerability of VYD2311 vs mRNA COVID vaccine through Day 6.
- Topline data expected in Q3 2026, potentially alongside DECLARATION pivotal trial data.
- VYD2311 is engineered from same backbone as pemivibart (EUA for immunocompromised PrEP) and adintrevimab.
- DECLARATION trial (n~2,400) is placebo-controlled evaluating VYD2311 efficacy in preventing symptomatic COVID.
- No efficacy or safety data released yet; forward-looking statements only.
Financial Impact
No financial data disclosed; clinical milestone with no revenue or cost figures.
Risk Factors
- LIBERTY or DECLARATION may fail to show superiority or non-inferiority vs vaccine/placebo.
- Regulatory pathway uncertain; FDA may require additional trials for BLA.
- Viral evolution could reduce VYD2311 neutralizing activity.
- Low historical win rate (29% T+20) on IVVD reports suggests market skepticism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312427 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $0.8800 $0.8441 | ▼ −4.08% | ▼ −5.26% | $0.8221 (−6.58%) |
Aug 17, 2026 6w ago | 144 | $0.8680 $0.8198 | ▼ −5.55% | ▼ −4.56% | $0.8221 (−5.29%) |
Jul 6, 2026 12w ago | 8-K | $0.8340 $0.5350 | ▲ +35.85% | ▲ +35.29% | $0.8221 (+1.43%) |
Jun 16, 2026 15w ago | Press Release | $0.8918 $0.8008 | ▼ −10.20% | ▼ −10.40% | $0.8221 (−7.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.8125 $0.8037 | ▼ −1.08% | ▼ −2.97% | $0.8221 (+1.18%) |
Jun 9, 2026 16w ago | Press Release | $0.9900 $0.9418 | ▼ −4.87% | ▼ −6.32% | $0.8221 (−16.96%) |
Jun 1, 2026 17w ago | Press Release | $1.22 $0.8724 | ▼ −28.49% | ▼ −27.19% | $0.8221 (−32.61%) |
May 14, 2026 20w ago | 8-K | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
May 14, 2026 20w ago | Press Release | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
Apr 9, 2026 25w ago | 8-K | $1.78 $1.46 | ▼ −17.98% | ▼ −25.55% | $0.8221 (−53.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access